Society News
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
-
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent.
-
US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.
-
New Combination Therapies Mean More Options, Challenge Decision-Making
Dr. Susan Scott discusses how findings from the MARIPOSA and FLAURA-2 trials will be incorporated into clinical practice.
-
Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment.
-
New, Indisputable Data Demonstrate Smoking Cessation Should be Considered a First-Line Therapeutic Intervention for Thoracic Malignancies
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival.
-
Amivantamab-Vmjw Plus Lazertinib Shows Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib Alone
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer.
-
In Brief for January 22, 2025
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection.
-
Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials.
View ILCN Archives
Provider Resources